Wedge Capital Management L L P NC Reduces Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Wedge Capital trimmed its stake in Gilead by 4.4% in Q4, selling 10,133 shares and leaving it with 217,711 shares valued at about $26.72 million.
• Insider selling has been notable: company insiders sold 309,280 shares (~$44.07M) over the past 90 days, including CFO Andrew D. Dickinson (3,000 shares) and CEO Daniel P. O'Day (10,000 shares).
• Gilead beat quarterly EPS and set FY‑2026 guidance of $8.45–$8.85, raised its quarterly dividend to $0.82 (annual $3.28, yield ~2.4%), and agreed to acquire Ouro Medicines for up to about $2.18 billion to expand its immunology/inflammation pipeline.

Wedge Capital Management L L P NC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 217,711 shares of the biopharmaceutical company's stock after selling 10,133 shares during the quarter. Wedge Capital Management L L P NC's holdings in Gilead Sciences were worth $26,722,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Trivium Point Advisory LLC boosted its stake in Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company's stock worth $813,000 after purchasing an additional 83 shares during the period. Binnacle Investments Inc boosted its position in shares of Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company's stock valued at $87,000 after acquiring an additional 83 shares during the period. Hemington Wealth Management grew its stake in Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company's stock valued at $110,000 after acquiring an additional 85 shares in the last quarter. Ignite Planners LLC increased its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock worth $880,000 after acquiring an additional 86 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Gilead Sciences by 0.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company's stock worth $3,912,000 after purchasing an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the chief financial officer owned 179,191 shares of the company's stock, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 309,280 shares of company stock worth $44,068,850 over the last 90 days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

GILD opened at $134.25 on Friday. The stock has a 50-day moving average price of $144.09 and a 200-day moving average price of $128.57. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $166.63 billion, a P/E ratio of 19.83, a PEG ratio of 1.79 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Ouro Medicines for up to about $2.18B to expand its inflammation/immunology franchise, strengthening longer‑term growth optionality beyond established HIV and antiviral products. Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
• Positive Sentiment: Gilead has been adding immunology and CAR‑T assets to diversify its pipeline and bolster oncology exposure — a strategic shift that could lift medium/long‑term revenue growth if integration and clinical readouts succeed. Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
• Positive Sentiment: Gilead recently reported an earningsbeat and set FY‑2026 EPS guidance in the $8.45–$8.85 range, signaling stable profitability and management confidence; consensus still trails that guidance, which supports valuation. Gilead Sciences Trading / Company Report
• Positive Sentiment: Erste Group nudged up its FY‑2026 EPS forecast for Gilead, a modest analyst raise that reinforces hopes for better-than-consensus earnings next year.
• Neutral Sentiment: Analyst consensus (average brokerage recommendation) sits at a Buy — helpful context but potentially already reflected in the share price; take analyst ratings as background, not a catalyst. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Zacks highlights Gilead as a value‑oriented pick under its style scores, which may attract income/value investors but is not an immediate price driver. Here's Why Gilead Sciences (GILD) is a Strong Value Stock
• Neutral Sentiment: Industry event notices (e.g., SK pharmteco symposium) are peripheral to Gilead’s near‑term stock movement and unlikely to be material. SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium
• Negative Sentiment: Market skepticism: analyst optimism and “Buy” consensus could be priced in, and investors may be trimming positions after recent gains (Gilead has traded near a 52‑week high in the past year), leading to downward pressure. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Deal risk and near‑term cost: the ~ $2.2B acquisition and other purchases increase upfront cash outlays and execution risk (integration, trial outcomes), which can weigh on the stock until benefits are demonstrated.
• Negative Sentiment: Technical/flow factors: trading volume is below the stock’s average and the price is below the 50‑day moving average, consistent with the current down move and limited buying momentum.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GILD shares. Scotiabank upped their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a report on Wednesday, February 11th. Wolfe Research boosted their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, February 12th. Daiwa Securities Group raised their price target on Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the stock a "buy" rating in a report on Wednesday, February 11th. Finally, Truist Financial raised their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.